A systematic review and meta-analysis of 27 studies also showed that SGLT-2 inhibitors reduced the risk of renal and cardiovascular disease impairment in patients with chronic kidney disease and patients with diabetes [28]. The gene discussed is SLC5A2; the disease is diabetes mellitus.